Chardan

3 Moderna Analyst Takes On The Coronavirus Vaccine Developer's Pipeline
Moderna Analysts Say COVID-19 Vaccine Contract Reflects Pricing Risk, Shows Ability To Scale
Moderna Analyst Breaks Down Biopharma's Coronavirus Vaccine Pricing
Moderna Analysts Say COVID-19 Vaccine Contract Reflects Pricing Risk, Shows Ability To Scale
Moderna Analyst Breaks Down Biopharma's Coronavirus Vaccine Pricing
How Moderna's Patent Challenge Loss Could Impact Coronavirus Vaccine Program
Adverum Biotech Shares Move Higher On Positive Wet AMD Gene Therapy Data

Chardan Recent News

Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal
Chardan: Tocagen's Brain, Spinal Cord Tumor Candidate Has $877M Potential
Chardan Stays Bullish On Vuzix After Q2 Print
Sarepta's Clinical Hold Could Be A Solid Biosciences Catalyst, Says Bullish Chardan Analyst
Analyst: Solid Biosciences A Solid Buy On Sarepta's Progress
3 Possible Outcomes From The Clinical Hold On Crispr Therapeutics's Sickle Cell Candidate
Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure
Chardan: Assembly Biosciences Hep B Antiviral Data 'Positive,' But Undifferentiated From Competitor Johnson & Johnson
Analyst: AveXis M&A Could Support Interest In Regenxbio
Chardan: Why The Novartis-AveXis Acquisition Is Good News For The Gene Therapy Space
Pair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over Axovant
Chardan: After Dicerna Pharma's 370% Run, Wait For Better Entry Point
Novavax Shares Rise 30% On Positive Data, But Risks Remain
Analyst Lifts Catalyst Biosciences PT From $10 To $75 On Hemophilia B Product
Chardan: Solar Decision Removes Uncertainty For Sunworks Investors
After A Freefall In Axovant Shares, Chardan Upgrades
For Smart Glasses Maker Vuzix, 2018 Could Be 'Transformative'
There Could Be 109% Upside In uniQure As Company Advances Gene Therapy Into Clinical Trials
Sage Therapeutics Falls Hard After Brexanolone Drug Fails Phase III Testing
Medicines Company Gets FDA Approval, Has 119% Upside According To This Analyst
Novovax Update Fails To Impress; This Is Now A 'Show Me Story'
A Barrage Of Biotech Updates Expected At ISTH Meeting
Analyst On Teladoc Acquisition Of Best Doctors: 'We Like It'